ATHA Insider Trading Activity and SEC Form 4 Filings
ATHA insider trading summary
Over the past 12 months, insiders at Athira Pharma, Inc. (ATHA) reported 5 sales worth $43K by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $43K.
Latest ATHA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 2, 2026 | Mark Worthington | General Counsel and CCO | Sell | $6K (876 @ $6.88) |
| Jan 2, 2026 | Mark James Litton | President and CEO | Sell | $18K (2,586 @ $6.88) |
| Jan 2, 2026 | Martin Javier San | Chief Medical Officer | Sell | $11K (1,644 @ $6.88) |
| Jan 2, 2026 | Kevin Church | Chief Scientific Officer | Sell | $6K (876 @ $6.88) |
| Jan 2, 2026 | Robert Renninger | Chief Financial Officer | Sell | $2K (297 @ $6.88) |
| Jul 1, 2025 | Mark James Litton | President and CEO | Sell | $7K (25,123 @ $0.29) |
| Jul 1, 2025 | Mark Worthington | General Counsel and CCO | Sell | $3K (8,526 @ $0.29) |
| Jul 1, 2025 | Kevin Church | Chief Scientific Officer | Sell | $3K (8,526 @ $0.29) |
| Jul 1, 2025 | Robert Renninger | SVP, Finance and Accounting | Sell | $850 (2,897 @ $0.29) |
| Jul 1, 2025 | Martin Javier San | Chief Medical Officer | Sell | $3K (10,842 @ $0.29) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.